RecruitingRecruiting
An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
NCT07329673 · Qbtech AB
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms.
About this study
This study aims to evaluate the performance of QbMobile in children, adolescents, and adults assessed for and diagnosed with ASD (Autism Spectrum Disorder, MDD (Major Depressive Disorder), Bipolar Disorder, or Anxiety Disorder, or has a prior diagnosis of one of the included disorders but is not currently receiving treatment. Participants will complete the 10-minute QbMobile test on their personal device during a scheduled clinical visit. They will then repeat the test remotely the following day at the same time as the previous test +/-3 hours. Participants will be asked to complete QbMobile prior to initiating any treatment.
Note on Outcome Measures Presentation:
The IRB-approved protocol defines endpoints broadly (e.g., identification of QbMobile domain profiles, classification accuracy, variability, and exploratory analyses). To comply with ClinicalTrials.gov requirements that each outcome measure represent a single assessment with a single unit of measure, these endpoints are operationalized into separate outcome measures corresponding to individual QbMobile metrics (domain SD-scores, Total Score \[0-100\], accuracy percentages, variability estimates).
This operationalization does not introduce new scientific endpoints or alter study objectives, design, or analyses. It ensures clarity and compliance for registry reporting while maintaining alignment with the approved protocol.
Eligibility criteria
Inclusion Criteria:
* Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile;
* Aged \> 6 years and \< 60 years old;
* Referred for an initial assessment for ASD, MDD, Bipolar Disorder or Anxiety Disorder (Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)) or has a prior diagnosis of one of the included disorders but is not currently receiving treatment;
* Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ASD, MDD, Bipolar Disorder or Anxiety Disorder per sites standard clinical procedures;
* Have adequate sensory and physical ability to complete QbMobile;
* Possess or have access to an iPhone model that supports QbMobile.
Exclusion Criteria:
* Intellectual disability designated by IQ\<70;
* Has a DSM-5 or ICD-11 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder due to another medical condition, PTSD, antisocial personality disorder, or borderline personality disorder;
* Has a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation);
* Has a concurrent medical diagnosis that could significantly affect test performance such as brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g. vascular dementia, Alzheimer disease, etc);
* Has other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain);
* Use of prescription medications (e.g., anxiolytics, sedative medications) taken on the day before completing QbMobile that could significantly affect performance;
* Substance use (e.g., alcohol, drugs) that may affect performance on the day of the tests.
Study design
Enrollment target: 300 participants
Age groups: child, adult
Timeline
Starts: 2026-01-01
Estimated completion: 2026-11
Last updated: 2026-05-06
Interventions
Device: Digital software application for cognitive performance and activity measurement (QbMobile, investigational device)
Primary outcomes
- • Identification of QbMobile Domain Profiles Using SD-Scores and Total Score (0-100) (Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2))
Sponsor
Qbtech AB · industry
Contacts & investigators
ContactRobert Nolen · contact · robert.nolen@qbtech.com · 18325370300
ContactRagini Sanyal · contact · ragini.sanyal@qbtech.com
All locations (1)
CCM Clinical Research GroupRecruiting
Miami, Florida, United States